Whitlock G, Lewington S, Sherliker P et al (2009) Prospective Studies Collaboration. Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. Lancet 373:1083–1096

Article  PubMed  Google Scholar 

Calle EE, Kaaks R (2004) Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer 4:579–591

Article  CAS  PubMed  Google Scholar 

Lumeng CN, Saltiel AR (2011) Inflammatory links between obesity and metabolic disease. J Clin Invest 121:2111–2117

Article  CAS  PubMed  PubMed Central  Google Scholar 

Logan CY, Nusse R (2004) The Wnt signaling pathway in development and disease. Annu Rev Cell Dev Biol 20:781–810

Article  CAS  PubMed  Google Scholar 

Gordon MD, Nusse R (2006) Wnt signaling: multiple pathways, multiple receptors, and multiple transcription factors. J Biol Chem 281:22429–22433

Article  CAS  PubMed  Google Scholar 

Barchetta I, CiminiCapoccia FA et al (2017) WISP1 is a marker of systemic and adipose tissue inflammation in dysmetabolic subjects with or without type 2 diabetes. J Endocr Soc 1:660–670

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang AR, Yan XQ, Zhang C, Du CQ, Long WJ, Zhan D, Ren J, Luo XP (2018) Characterization of Wnt1-inducible signaling pathway protein-1 in obese children and adolescents. Curr Med Sci 38:868–874

Article  CAS  PubMed  Google Scholar 

Jung TW, Kang C, Goh J, Chae SI, Kim H-C, Lee TJ, Abd El-Aty AM, Jeong JH (2018) WISP1 promotes non-alcoholic fatty liver disease and skeletal muscle insulin resistance via TLR4/JNK signaling. J Cell Physiol 233:6077–6087

Article  CAS  PubMed  Google Scholar 

Klimontov VV, Bulumbaeva DM, Fazullina ON, Lykov AP, Bgatova NP, Orlov NB, Konenkov VI, Pfeiffer AFH, Pivovarova-Ramich O, Rudovich N (2020) Circulating Wnt1-inducible signaling pathway protein-1 (WISP-1/CCN4) is a novel biomarker of adiposity in subjects with type 2 diabetes. J Cell Commun Signal 14:101–109

Article  PubMed  Google Scholar 

Schauer PR, Bhatt DL, Kirwan JP et al (2017) Bariatric surgery versus intensive medical therapy for diabetes -5-year outcomes. N Engl J Med 376(7):641–651

Article  PubMed  PubMed Central  Google Scholar 

Buchwald H, Buchwald JN (2019) Metabolic (bariatric and nonbariatric) surgery for type 2 diabetes: a personal perspective review. Diabetes Care 42(2):331–340

Article  PubMed  Google Scholar 

Aroda VR (2018) A review of GLP-1 receptor agonists: evolution and advancement, through the lens of randomised controlled trials. Diabetes Obes Metab 20(Supplement 1):22–33

Article  CAS  PubMed  Google Scholar 

Jirapinyo P, Jin DX, Qazi T, Mishra N, Thompson CC (2018) A meta-analysis of GLP-1 after Roux-en-Y gastric bypass: impact of surgical technique and measurement strategy. Obes Surg 28(3):615–626

Article  PubMed  Google Scholar 

Ye J, Hao Z, Mumphrey MB (2014) Mumphrey et al. “GLP-1 receptor signaling is not required for reduced body weight after RYGB in rodents. Am J Physiol 306(5):R352–R362

CAS  Google Scholar 

Wilson-Pérez HE, Chambers AP, Ryan KK et al (2013) Vertical sleeve gastrectomy is effective in two genetic mouse models of glucagon-like peptide 1 receptor deficiency. Diabetes 62(7):2380–2385

Article  PubMed  PubMed Central  Google Scholar 

Andrew CA, Umashanker D, Aronne LJ, Shukla AP (2018) Intestinal and gastric origins for diabetes resolution after bariatric surgery. Curr Obes Rep 7(2):139–146

Article  PubMed  Google Scholar 

Chang JS, Kim TH, Kong ID (2020) Exercise intervention lowers aberrant serum WISP-1 levels with insulin resistance in breast cancer survivors: a randomized controlled trial. Sci Rep 10(1):10898

Article  CAS  PubMed  PubMed Central  Google Scholar 

Murahovschi V, Pivovarova O, Ilkavets I, Dmitrieva RM, Döcke S, Keyhani-Nejad F, Gögebakan Ö, Osterhoff M, Kemper M, Hornemann S, Markova M, Klöting N, Stockmann M, Weickert MO, Lamounier-Zepter V, Neuhaus P, Konradi A, Dooley S, von Loeffelholz C, Blüher M, Pfeiffer AF, Rudovich N (2015) WISP1 is a novel adipokine linked to inflammation in obesity. Diabetes 64(3):856–866

Article  CAS  PubMed  Google Scholar 

Hörbelt T, Tacke C, Markova M, Herzfeld de Wiza D, Van de Velde F, Bekaert M, Van Nieuwenhove Y, Hornemann S, Rödiger M, Seebeck N, Friedl E, Jonas W, Thoresen GH, Kuss O, Rosenthal A, Lange V, Pfeiffer AFH, Schürmann A, Lapauw B, Rudovich N, Pivovarova O, Ouwens DM (2018) The novel adipokine WISP1 associates with insulin resistance and impairs insulin action in human myotubes and mouse hepatocytes. Diabetologia 61(9):2054–2065

Article  PubMed  Google Scholar 

Ferrand N, Bereziat V, Moldes M, Zaoui M, Larsen AK, Sabbah M (2017) WISP1/CCN4 inhibits adipocyte differentiation through repression of PPARγ activity. Sci Rep 7:1749

Article  PubMed  PubMed Central  Google Scholar 

Spalding KL, Arner E, Westermark PO et al (2008) Dynamics of fat cell turnover in humans. Nature 453:783–787

Article  CAS  PubMed  Google Scholar 

Mirr M, Owecki M (2021) An update to the WISP-1/CCN4 role in obesity, insulin resistance and diabetes. Medicina 57(2):100

Article  PubMed  PubMed Central  Google Scholar 

Recarte M, Corripio R, Palma S, Mata A, de Cos AI (2023) Improvement of low-grade inflammation in patients with metabolically healthy severe obesity after primary bariatric surgery. Obes Surg 33(1):38–46

Article  PubMed  Google Scholar 

Villarreal-Calderon JR, Cuellar-Tamez R, Castillo EC, Luna-Ceron E, García-Rivas G, Elizondo-Montemayor L (2021) Metabolic shift precedes the resolution of inflammation in a cohort of patients undergoing bariatric and metabolic surgery. Sci Rep 11(1):12127

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wu H, Ballantyne CM (2017) Skeletal muscle inflammation and insulin resistance in obesity. J Clin Invest 127(1):43–54

Article  PubMed  PubMed Central  Google Scholar 

Petersen KF et al (2007) The role of skeletal muscle insulin resistance in the pathogenesis of the metabolic syndrome. Proc Natl Acad Sci U S A 104(31):12587–12594

Article  CAS  PubMed  PubMed Central  Google Scholar 

Petersen KF, Shulman GI (2002) Pathogenesis of skeletal muscle insulin resistance in type 2 diabetes mellitus. Am J Cardiol 90(5A):11G-18G

Article  CAS  PubMed  Google Scholar 

Lorenzo M, Fernández-Veledo S, Vila-Bedmar R, Garcia-Guerra L, De Alvaro C, Nieto-Vazquez I (2008) Insulin resistance induced by tumor necrosis factor-alpha in myocytes and brown adipocytes. J Anim Sci 86(14 suppl):E94–E104

Article  CAS  PubMed  Google Scholar 

Bouzakri K, Koistinen HA, Zierath JR (2005) Molecular mechanisms of skeletal muscle insulin resistance in type 2 diabetes. Curr Diabetes Rev 1(2):167–174

Article  CAS  PubMed  Google Scholar 

DeFronzo RA, Tripathy D (2009) Skeletal muscle insulin resistance is the primary defect in type 2 diabetes. Diabetes Care 32(suppl 2):S157–S163

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kaminska B (2009) Molecular characterization of inflammation-induced JNK/c-Jun signaling pathway in connection with tumorigenesis. Methods Mol Biol 512:249–264

Article  CAS  PubMed